HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)

Protara Therapeutics (NASDAQ:TARA)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $23.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 472.14% from the stock’s previous close. HC Wainwright also issued estimates for Protara Therapeutics’ FY2029 earnings at ($0.73) EPS.

Separately, Guggenheim reissued a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $4.02 on Thursday. The business’s 50 day moving average price is $4.56 and its 200-day moving average price is $3.41. The firm has a market capitalization of $82.93 million, a PE ratio of -1.43 and a beta of 1.69. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. As a group, analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in shares of Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock valued at $948,000 after purchasing an additional 9,553 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after purchasing an additional 17,572 shares during the last quarter. HBK Investments L P acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $106,000. Squarepoint Ops LLC acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $110,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $111,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.